English (United Kingdom)

https://curated-unify.zendy.io/wp-json/zendy-region/v1/featured_content/oa?rat=en

https://curated-unify.zendy.io/wp-json/zendy-region/v1/highlighted_journal/

Global: Zendy Plus annual

Presents the access of premium content as premium feature

Premium Content

Presents the keyphrase highlighting as premium feature

Keyphrase Highlighting

Presents the summarisation as premium feature

Summarisation

Insights

Presents the pdf analysis as premium feature

PDF Analysis

Presents the zaia usage as premium feature

ZAIA

Global: Zendy Tools annual

Global: Zendy Free Plan

Global: Zendy Tools monthly

Global: Zendy Plus monthly

espanolLa enfermedad de Castleman es una entidad patologica rara, que abarca un grupo heterogeneo de desordenes histopatologicos de los ganglios linfaticos. Puede clasificarse en enfermedad de Castleman unicentrica, cuando se trata del crecimiento de un solo ganglio linfatico o de ganglios linfaticos de una misma region, o en enfermedad de Castleman multicentrica si afecta adenopatias de diferentes regiones ganglionares. Ambos tipos de enfermedad de Castleman difieren en cuanto a incidencia, epidemiologia y curso clinico. La enfermedad de Castleman unicentrica tiene una incidencia calculada en Estados Unidos entre 15.9 a 19.9 casos por millon personas-ano, se presenta principalmente en personas jovenes, alrededor de la tercera decada de la vida y es mas frecuente en mujeres. Los factores causales de esta patologia son desconocidos. Las manifestaciones clinicas dependen de la variante histologica, siendo mas frecuente la variante hialino vascular, que suele ser asintomatica. El diagnostico confirmatorio de la enfermedad de Castleman unicentrica es histologico. La reseccion nodular completa es el tratamiento de eleccion, mientras que en las lesiones no resecables la radioterapia y la quimioterapia son opciones terapeuticas. El pronostico de la enfermedad es benigno, con una mortalidad asociada a 10 anos del 4% y porcentajes de curacion que rondan el 95%. EnglishCastleman’s disease is a rare pathological entity, which comprises a heterogeneous group of histopathological disorders of the lymph nodes. It can be classified as unicentric Castleman’s disease, when it involves the growth of a single lymph node or lymph nodes of the same region, or in multicentric Castleman’s disease if it affects adenopathies of different ganglionic regions. Both types of Castleman’s disease differ in incidence, epidemiology, and clinical course. The unicentric Castleman disease has an estimated incidence in the United States between 15.9 to 19.9 cases per million person-years, occurs mainly in young people, around the third decade of life and is more frequent in women. The causal factors of this pathology are unknown. The clinical manifestations depend on the histological variant, with the hyaline vascular variant being more frequent, which is usually asymptomatic. The confirmatory diagnosis of the unicentric Castleman disease is histological. Complete nodular resection is the treatment of choice, while radiotherapy and chemotherapy are therapeutic options for non-resectable lesions. The prognosis of the disease is benign, with an associated mortality to 10 years of 4% and percentages of cure around 95%.

Enfermedad de castleman unicéntrica: revisión breve de una enfermedad poco conocida